Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For those that believe they can lie, distort, smear, be immoral, unethical without consequences??
What was the 'quirky' saying? "Choose wisely grasshopper'...
Watched this movie a couple of times... this short video IF you are open minded, should make you wonder..
and question WHO YOU ARE, WHAT YOU ARE...
Below aren't all of the shorts returned, however there is an indication they could be almost finished returning whatever isn't already failed to deliver.
1 hour ago 2024-04-23 13:14:40.777 400,000
1 hour ago 2024-04-23 12:42:51.205 350,000
2 hours ago 2024-04-23 12:11:06.263 300,000
2 hours ago 2024-04-23 11:39:00.513 3,200,000
3 hours ago 2024-04-23 10:33:57.772 3,300,000
4 hours ago 2024-04-23 10:01:37.768 3,400,000
4 hours ago 2024-04-23 09:29:37.985 3,300,000
5 hours ago 2024-04-23 08:57:51.034 3,400,000
7 hours ago 2024-04-23 06:50:16.602 4,500,000
10 hours ago 2024-04-23 04:10:22.814 4,300,000
Exhibiting is not the same als presenting a late breaking abstract
KEEP PRAYING SENIOR, THIS IS A DOG THAT'S GOT FLEES !!
Not currently...sold out in mid .19s the day it went to .26...not sure what I will do from here...never know I might be back in at the bell.
Knock on wood, if my analysis is correct, oh man lol the MA200 Exponential is within reach.
Isn't it already confirmed they'll be present at the ASCO?
https://asco24.myexpoonline.com/exhibitors/exhibitor/779
I saw 1mil on ask .1485 yesterday....keep block it .....I guess he chase buy back
Ahhh interesting 🧐 ! Hey how r ya? Long time no see! R u in here?
If .15 is the new 23.6% Fibb support level , that would also make the previous high of .25 the new 50% breakout level. I will be watching this very closely. *THIS IS NOT FINANCIAL ADVICE* I'm literally reading data on a chart using my own tools.
I wish I could have 1 million shares, that's my one lofty goal haha :D
Sorry I shouldn't assume its one person.. its the same person/entity who filled at around .16-.165 the other day. They're is steadily accumulating millions of shares
I saw 930 000 shares filled in less than 1 minute on Webull
There is a massive order being filled right now at .16 average price.
Shorts know they can not win this against P3 data... So I hope for ASCO announcement, that gives them 5 weeks time to cover everything, which should be more than enough
I'm sure they're having daily meetings about how to release PR and new info, it's all about having a plan and executing the strategy. I believe in this company and my gut tells me they're playing chess. They have to be aware of the MASSIVE short position against them and the only way to fight it is with fire
Also the fact that they waited to PR that Napo is exhibiting at ONS , starting tomorrow, indicates that they are timing their PR's right now. I wouldn't be surprised to hear more from them today, and tomorrow they can announce if ASCO has accepted ONTARGET results
We still don't have a US partnership... I am looking at South America, China ... 2 huge markets left, maybe aswell India/Indonesia? Australia?
I'm assuming we will be seeing more news come out. That is a large offering in the S-3 filed yesterday. Nasdaq took their $20k for the hearing and didn't even have one, they just granted them an extension without it. Multiple partnerships have been announced since the extension was granted.
Being gorgeous and beautiful does not stop you from being a moron....it only gives a free pass of being one....LOL
Curious if we will see another PR in pre market today
I am glad you don't call it a real offering. I think even shorts know what a mixed offering is about.
The timing (again) is slowing the progress. The only acceptable reason to do this, is with good news coming.
So, if I am right and ASCO is the target, we will know tomorrow. Announcement AH or PM thursday, I have to look up, but than we can see what this is all about
agree but some idiots pumpers here are blind
CEO looks gorgeous and beautiful....why u call her moron CEO???🤪
Haha....of course they wrecked the rally. Even though it's not a real offering , just an intention to sell more shares. Why put that out there now ? Friggin idiots. Anything to slow down the rally. What a great job you moron CEO.
Ban ngi Sao ve filing? Minh mua vao after hour .15
They were being transparent enough to where they probably would’ve mentioned that they did say there’s other means they will use to raise revenue, common shares, preferred shares, etc. it would make sense they would raise the AS a little bit first they don’t have to do a drastic reverse split with that low of an OS….
WHAT A DOD !! WHAT ADOG !! DOGGY...DOGGY !!!
Actually, the smaller the share count, the better it can be going forward...
Less shares to divide the earnings against, helps make the earnings/sh look good vs a higher share count
Also, the less shares there are, the more 'volatile' the share price moves can be IF there is a scramble to get shares..
Can make things quite exciting if the company announces a 'good' PR when it was least expected..
and folks want shares for a longer term hold..
Never mind. They’ve done 4 splits since 2018. I thought the sec wouldn’t allow splits very year. What sense would it make to reverse with only 274m shares. 1/10 would only leave 27 mil shares. Doesn’t make sense. The nasdaq doesn’t allow the BS allowed in otc.
They just did a r/s in Jan of 23. They can only do one very 4 to 5 years by Feb rules right?
That is exactly what's going to take place.They know the results are good.All we need now is the ratio.I think the news comes first,to get the pop.That way the RS ratio depends how high it goes.The RS will then be done over a weekend,with the offering.Good luck and good trading.
almost sounds like they are setting the 'table' for the following SEQUENCE of events:
r/split to elevate the share price, followed by PR to draw interest to the shares, and then start quietly start selling pre-authorized shares for cash (ATM)
Have no problem with this as long as it supports them in their effort to generate revenues and get the bigger players on Wall Street looking at the shares because the price is not at the penny stock level.
Only question is, at what price does it happen and how hard is the hit to each of ours share count..
Great news - this shelf offerring may be the company just positioning itself for good news - phase 3 outcomes, or maybe a merger. All is well from my perspective.
Did I read it right? They’ve only diluted 10 million shares since April 1 through all those shares traded only 10 million added to the OS and the 75 million that they’re gonna raise isn’t just held to common shares. The OS was 2 76 million April 1 and in that report it shows 286 interesting
Some whispering nearby ...
Do not sell.
Yeah, you gotta respect the company that tells you it’s gonna sell some shares here and there rather than a company that just does it.they all sell shares they all raise money. That’s why they’re in the OTC. They did give updated OS count which means they haven’t really deluted that much.
Wow, missed the action while driving. This is great news. Shelf offering way better than public but there is some public in the file. Most is shelf though. Someone knows something and expects price to skyrocket 🚀🚀🚀🚀
Just getting their ducks in a row.Once they announce results,stock will spike higher,then the offering will be done.In this way they will maximize the funds.This tells me they are about to report some positive news that will spike the share price.Good luck and good trading.
$JAGX mixed shelf only, no offering currently but potential for upcoming, near future Offering.
Filing out...do u see?
Just some idiot selling at market.People, place your sell orders at a limited price.Good luck and good trading.
my advice would be to relax its a long term hold for real gains.
Good luck everyone I m out. Tough to break .20
Please release contract or partnership news!
When do u plan to sell?
If it breaks .2 than I consider real!
Followers
|
148
|
Posters
|
|
Posts (Today)
|
25
|
Posts (Total)
|
5874
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |